Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:ARTL NASDAQ:CDT NASDAQ:GNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.15+4.1%$6.64$5.41▼$12.05$8.46M1.514,799 shs318 shsARTLArtelo Biosciences$2.34+1.3%$4.92$2.30▼$85.80$2.17M0.051.87 million shs84,081 shsCDTCDT Equity$1.86-12.3%$7.04$1.77▼$1,224.00$10.30M1.675,920 shs62,299 shsGNPXGenprex$0.86+1.2%$1.45$0.81▼$55.00$8.87M-0.941.27 million shs290,173 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+0.92%+5.99%-0.69%-2.76%-11.50%ARTLArtelo Biosciences+1.30%-12.69%-56.75%-35.00%-86.93%CDTCDT Equity-12.26%-10.58%-61.01%-93.11%-99.85%GNPXGenprex+1.20%-0.43%-28.82%-57.36%-92.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.15+4.1%$6.64$5.41▼$12.05$8.46M1.514,799 shs318 shsARTLArtelo Biosciences$2.34+1.3%$4.92$2.30▼$85.80$2.17M0.051.87 million shs84,081 shsCDTCDT Equity$1.86-12.3%$7.04$1.77▼$1,224.00$10.30M1.675,920 shs62,299 shsGNPXGenprex$0.86+1.2%$1.45$0.81▼$55.00$8.87M-0.941.27 million shs290,173 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+0.92%+5.99%-0.69%-2.76%-11.50%ARTLArtelo Biosciences+1.30%-12.69%-56.75%-35.00%-86.93%CDTCDT Equity-12.26%-10.58%-61.01%-93.11%-99.85%GNPXGenprex+1.20%-0.43%-28.82%-57.36%-92.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 1.00SellN/AN/AARTLArtelo Biosciences 1.67Reduce$54.002,207.69% UpsideCDTCDT Equity 1.00SellN/AN/AGNPXGenprex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ARTL, CDT, GNPX, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026ADXNAddex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K19.12N/AN/A$10.37 per share0.69ARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/ACDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/AGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$5.74N/AN/AN/AN/A-80.69%-69.69%5/25/2026 (Estimated)ARTLArtelo Biosciences-$12.88M-$62.76N/AN/AN/AN/A-3,401.09%-345.03%5/19/2026 (Estimated)CDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/AGNPXGenprex-$16.23M-$26.50N/AN/AN/AN/A-495.78%-285.92%N/ALatest ARTL, CDT, GNPX, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ARTLArtelo Biosciences-$0.78-$4.00-$3.22-$4.00N/AN/A5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AARTLArtelo BiosciencesN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A2.012.01ARTLArtelo BiosciencesN/A0.170.17CDTCDT EquityN/A0.340.34GNPXGenprexN/A3.843.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ARTLArtelo Biosciences0.87%CDTCDT Equity3.29%GNPXGenprex14.05%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ARTLArtelo Biosciences11.50%CDTCDT Equity10.78%GNPXGenprex0.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.23 million1.05 millionNot OptionableARTLArtelo Biosciences5940,000830,000Not OptionableCDTCDT Equity34.86 million4.33 millionNot OptionableGNPXGenprex2010.42 million10.39 millionNo DataARTL, CDT, GNPX, and ADXN HeadlinesRecent News About These CompaniesGenprex Announces Positive Preclinical Data for Diabetes Gene TherapyMay 14 at 8:51 AM | tipranks.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingMay 14 at 8:00 AM | prnewswire.comGenprex Expands Reqorsa Cancer Therapy Patent Protection in IsraelApril 30, 2026 | tipranks.comGenprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerApril 30, 2026 | prnewswire.comGenprex Highlights Promising Preclinical Data for Diabetes Gene TherapyApril 28, 2026 | tipranks.comGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingApril 28, 2026 | prnewswire.comPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual MeetingApril 22, 2026 | prnewswire.comGenprex Expands Lung Cancer Gene Therapy Research CollaborationApril 21, 2026 | tipranks.comGenprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyApril 21, 2026 | prnewswire.comGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingApril 20, 2026 | prnewswire.comGenprex Insider Trading Activity | NASDAQ:GNPX | BenzingaApril 3, 2026 | benzinga.comGenprex Inc.March 19, 2026 | barrons.comGenprex Highlights New Reqorsa Preclinical Data at AACRMarch 18, 2026 | tipranks.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingMarch 18, 2026 | prnewswire.comGenprex to Participate at BIO Europe Spring 2026March 10, 2026 | prnewswire.comGenprex, Inc.: Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat CancerFebruary 23, 2026 | finanznachrichten.deGenprex stock jumps on Japan, Europe patent approvalsFebruary 23, 2026 | za.investing.comGenprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat CancerFebruary 23, 2026 | prnewswire.comGenprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersFebruary 10, 2026 | prnewswire.comGenprex Regains Nasdaq Compliance but Faces Ongoing MonitoringJanuary 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTL, CDT, GNPX, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$7.15 +0.28 (+4.08%) Closing price 05/14/2026 03:58 PM EasternExtended Trading$6.90 -0.25 (-3.55%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Artelo Biosciences NASDAQ:ARTL$2.34 +0.03 (+1.30%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.25 -0.09 (-3.85%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.CDT Equity NASDAQ:CDT$1.86 -0.26 (-12.26%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$1.92 +0.06 (+3.23%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Genprex NASDAQ:GNPX$0.86 +0.01 (+1.20%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.83 -0.03 (-3.17%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
